Background: Venous thromboembolism is a common condition in hospitalized medical patients. Numerous studies have demonstrated that low molecular weight heparin significantly reduces this risk but, despite this, the use of thromboprophylaxis remains poor. Aim: To evaluate the use of an exclusion based risk-assessment model (RAM) for venous thrombosis in improving the uptake of appropriate thromboprophylaxis in hospitalized medical patients. Design: A survey with a subsequent audit cycle of three separate audits over 36 months. Methods: 497 hospitalized patients with acute medical conditions on general medical wards were audited at a secondary care centre in London, UK. The survey and subsequent audits were performed by reviewing the notes and medication charts of medical patients, prior to the launch of the RAM and at 12, 28 and 36 months following its introduction.
Introduction
Venous thromboembolism (VTE) is a frequent cause of morbidity and mortality in hospitalized patients. At least 1% of hospitalized patients experience a pulmonary embolus and the rate of deep vein thrombosis (DVT) of the leg is much higher. 1, 2 Based on extensive autopsy data, pulmonary embolism (PE) is thought to be a contributing factor in 5-20% of hospital deaths. [2] [3] [4] [5] [6] Frequently, the diagnosis of thrombosis is not made ante-mortem, highlighting the need for effective prevention when an at-risk patient is admitted to hospital.
Although it is widely appreciated that surgical procedures are a leading cause of venous thrombosis, it is in fact hospitalized medical patients who experience the greatest burden of thromboembolic disease, with 50-70% of symptomatic VTE in hospital in-patients occurring in those with medical conditions. [7] [8] [9] Numerous articles have demonstrated the increased risk of VTE in patients with particular medical conditions, including severe congestive cardiac failure, acute infectious disease, myocardial infarction, ischaemic stroke, cancer, rheumatic disease and inflammatory disease. 4, [10] [11] [12] [13] [14] [15] [16] Hospitalized patients are at even greater risk if they have other predisposing conditions leading to VTE including previous history of VTE, advanced age, obesity and immobility. 4, 10, 18 It has been known for many years that surgical patients benefit from pharmacological thromboprophylaxis with heparin and it is now prescribed in up to 80-90% of appropriate cases. [19] [20] [21] [22] Recent large randomized controlled trials have now demonstrated the effectiveness of prophylactic low molecular weight heparin in preventing venous thrombosis in hospitalized medical patients with relative risk reductions of between 45% and 60%. 24, 25 However, despite this evidence, studies show that the uptake of appropriate thromboprophylaxis remains poor. 26, 27 Models for assessing individual risk of VTE in hospitalized medical patients have been proposed in an attempt to improve delivery of thromboprophylaxis to those in whom it is required. [28] [29] [30] However, these models are often complicated, requiring the physician to categorize the patient's risk using numerous factors before deciding whether the patient warrants thromboprophylaxis. It is likely that this has a bearing on its poor provision.
A simpler risk assessment scheme in the form of an exclusion model has been proposed to try to improve the uptake of appropriate thromboprophylaxis by hospital physicians. 31 In this model, all patients receive thromboprophylaxis unless they either fall outside a broad category that defines thrombosis risk or have a contraindication to pharmacological thromboprophylaxis. This attempts to make VTE risk assessment as straightforward and as efficient as possible, providing clear guidelines to clinicians as to which of their patients should receive thromboprophylaxis and offering an alternative to the risk assessment models (RAM) requiring calculations of thrombosis risk based on complex criteria.
We designed a similar exclusion-based RAM for all hospitalized medical patients at our Trust, following which audits were performed to determine whether the RAM had been effective at improving the use of appropriate thromboprophylaxis.
Methods
We designed an exclusion-based model for risk assessment for venous thrombosis in hospitalized medical patients. The aim was to create a proforma that was easy to use and clearly demonstrated to the medical teams which of their patients were at risk and the appropriate thromboprophylaxis to administer.
The proforma used the broad category of age >40 years and hospitalization with an acute medical illness as a requirement to receive thromboprophylaxis. Patients were excluded from receiving thromboprophylaxis if they did not fall within this broad category or if they had a contraindication to low molecular weight heparin. They were also asked to be considered for thromboprophylaxis if they had additional risk factors for VTE.
The patient category used for deciding who should receive thromboprophylaxis and additional risk factors were based on the guidelines from the American College of Chest Physicians and categories of at-risk patients used in the Medenox trial. 24, 25, 32 Enoxaparin (40 mg daily) was recommended as pharmacological thromboprophylaxis as per the Medenox trial. 25 Physicians were also asked to consider anti-embolism stockings in all patients and to review the dose of enoxaparin at extremes of body weight.
Exclusions to receiving low molecular weight heparin were: high risk of bleeding; the use of oral anti-coagulants with a therapeutic INR; creatinine clearance <30 ml/min when either unfractionated heparin or a lower dose of LMWH was recommended; previous or current heparin induced thrombocytopaenia (HIT) or current spinal/epidural anaesthesia.
The acute medical illnesses known to be associated with an increased risk of thrombosis and other risk factors for the development of VTE were listed on the back of the proforma to aid in decision making. 4, [10] [11] [12] [13] [14] [15] [16] [17] [18] The proforma was distributed in the form of double-sided pocket cards for junior medical staff to be able to carry with them and in single-sided posters on all wards admitting medical patients ( Figure 1) .
A survey was performed prior to the introduction of the RAM to assess current adherence to national guidelines. 32 Following the launch of the RAM, an audit was carried out to determine whether the RAM had been effective at improving the use of appropriate thromboprophylaxis. Appropriate thromboprophylaxis was defined as the patient either receiving or not receiving thromboprophylaxis as per the criteria of the proforma.
The survey and subsequent audits were performed by reviewing the notes and medication charts of medical patients, prior to the launch of the RAM and at 12, 28 and 36 months following its introduction.
Patients were excluded from the analysis if they were receiving treatment dose anti-coagulation in the form of a heparin or coumarin. Patients were also excluded if they were part of any trial involving anti-coagulation medication.
Statistical analysis was performed using chi-squared analysis on the comparison of appropriate thromboprophylaxis prior to and subsequent to the introduction of the RAM for each audit. A P-value of <0.01 was considered to be statistically significant.
Results
The notes and medication charts of medical patients throughout the hospital were reviewed over a 3-day period during the survey and each audit. One hundred and forty-five patients were reviewed prior to the introduction of the RAM. After the introduction of the RAM, 131, 114 and 107 patients were reviewed at 12, 28 and 36 months, respectively.
In the survey two patients were excluded. In the subsequent audits, 0, 15 and 28 patients were excluded, respectively, as shown below (Table 1) . Patients were recorded as having a VTE risk factor if any of the risk factors outlined in the RAM were documented in the patients' notes for the admission being audited. Table 1 gives the frequency of the VTE risk factors present in the patients analysed during the survey and each subsequent audit.
This provided 143, 131, 99 and 79 patients for analysis for the survey and each audit. Prior to the introduction of the RAM, appropriate thromboprophylaxis was prescribed in 49% cases. This had not improved 8 months after the introduction of the RAM (48%). However, uptake improved dramatically 18 and 24 months following the introduction of the RAM with appropriate thromboprophylaxis being prescribed in 71 and 76%, cases respectively. Both these audits demonstrated a statistically significant improvement in the prescribing of appropriate thromboprophylaxis when compared to that prior to the introduction of the RAM (P < 0.01) ( Table 2) .
The mean age of the patients in the survey and each of the three audits were 70.8, 69.0, 62.0 and 62.2 years, respectively. In the survey and three audits, the most common medical condition with which patients were hospitalized was acute infectious disease (20.9-57%). The most common additional risk factor for VTE was advanced age >75 years (31.3-50%) followed by immobility (19.5-30.3%).
The commonest reason for a contraindication to low molecular weight heparin was a high bleeding risk either associated with liver dysfunction causing a high INR or active bleeding in the form of gastrointestinal blood loss (Table 3) . Patients listed in this study as receiving oral anti-coagulation were excluded from the analysis.
In almost all of the cases where inappropriate thromboprophylaxis was given, this was a result of patients not receiving enoxaparin when it would have been appropriate to do so according to the proforma, rather than enoxaparin being given when it was incorrect to do so. The exception to this was in one case of diabetic ketoacidosis, when a patient under the age of 40 years had enoxaparin administered but fell outside the broad category to receive thromboprophylaxis.
Each survey and audit group was not identical when comparing the number of patients with each type of acute medical illness and individual risk factor for VTE between each group. For example, acute infectious disease and acute respiratory disease were underrepresented in the last two groups when compared with the first two. Furthermore advanced age was also differently represented between the first two and the last two groups.
In particular, patient numbers affected by stroke was significantly different between the survey and each subsequent audit group. In the survey and Audit One, 15.4 and 9.9% patients respectively, presented with stroke. However in Audit Two, no patients audited had presented with stroke and only two patients (2.5%) were suffering with stroke in the final audit. This discrepancy is important as in the survey and first audit, when overall administration of appropriate thromboprophylaxis was poor, there were a large proportion of patients presenting with stroke who were not given appropriate thromboprophylaxis. A subsequent analysis was therefore performed, removing all stroke patients and a reassessment of the effectiveness of the proforma reassessed as shown in Table 4 . The improvement in the use of appropriate thromboprophylaxis was still significant when Audits Two and Three were compared with the survey, performed prior to the introduction of the RAM. Stroke as a controversial area for the use of pharmacological thromboprophylaxis is discussed in the conclusion.
Anti-embolism stockings were rarely used. On the proforma it is recommended that they only be considered, as the evidence base for the use of stockings in medical patients is very poor. Eight patients were prescribed stockings in both the survey and Audit One, and only a single patient in each of Audits Two and Three. When stockings were used, inappropriate thromboprophylaxis had been given in 13 out of the 18 cases, 5 being in stroke patients.
Discussion
The use of an exclusion-based RAM for venous thrombosis in hospitalized medical patients appears to significantly and consistently improve the uptake of appropriate thromboprophylaxis. It is likely that this was as a result of using a proforma that was simple to use and made it clear to clinicians which of their patients were at risk of venous thrombosis and warranted low molecular weight heparin and in whom it was contraindicated. The new proforma was advertised across all medical wards in the form of large posters and pocket cards were given to all junior doctors who would be involved in the use of the RAM, so that reminders to use the proforma were always available to them. However, these measures alone appear to have been inadequate in improving the rate of appropriate thromboprophylaxis, as there was no improvement in thromboprophylaxis prescription 12 months following the introduction of the RAM. A decision was therefore made that all new junior doctors, on joining the Trust, would be educated in venous thrombosis prevention and the use of the RAM, by the senior coagulation pharmacist. This began 2 years after the introduction of the RAM and when the rate of appropriate thromboprophylaxis was audited 3 and 11 months after the teaching programme was introduced, this had increased significantly suggesting that education regarding the RAM was essential to its effective working in improving rates of prescription of appropriate thromboprophylaxis.
Many doctors in post at the time of the final audit would have been the same as those in post during Audit Two and therefore would have had the same level of training. It will be important to maintain this education programme when new doctors join the Trust so that high levels of thromboprophylaxis are maintained and eventually become universal. Annual audits of the rate of appropriate thromboprophylaxis will be essential to ensure that progress continues to be made, particularly as, despite improvements, the rate of appropriate thromboprophylaxis remains <100% in hospitalized medical patients at our Trust.
Limitations
One of the limitations of this study is the lack of documented evidence that medical patients were risk assessed for venous thrombosis using the RAM and therefore, as a result of the RAM, the rate of appropriate thromboprophylaxis improved. It therefore has to be considered what other interventions could have resulted in appropriate thromboprophylaxis rates improving over the time period studied, other than the introduction of the RAM and the junior doctors being educated in its use. Our Trust educates approximately 60 new junior doctors each year on the application of the RAM to hospitalized medical patients and the importance of venous thrombosis prevention in general. As far as we are aware, there were no new guidelines published during the audit, which reiterated the importance of VTE prevention in medical inpatients and to which junior doctors could have referred or senior members of their team recommended to them. The ACCP guidelines, for example, explain in detail the high risk of VTE in hospitalized medical patients and the need to prescribe LMWH to those at risk. 32 These guidelines were available throughout the duration of our audit and were not updated until the audit was complete. No other practices in VTE prevention changed at our hospital and we are unaware of any changes that have occurred in medical students' education locally or nationally which could have had an impact on the knowledge of VTE prevention of new junior doctors joining our trust over the period of the audit. We therefore believe that an absence of potential confounders, which could have had a positive effect on appropriate thromboprophylaxis, allow us to reasonably suggest that it was the RAM and the education of the junior doctors in its use that has led to the improvement in appropriate thromboprophylaxis rates.
Another limitation of this study is that the four patient groups reviewed during each audit were not heterogeneous for their presenting medical illnesses and other predisposing factors for venous thrombosis. In general, there is no reason why a lack of heterogeneity in these areas between the groups should affect the administration of thromboprophylaxis as if a particular patient group is at high risk of bleeding then this is covered by the RAM as a contraindication to receiving thromboprophylaxis. However, occasionally, this lack of heterogeneity could lead to bias when the administration of thromboprophylaxis is controversial. This is particularly highlighted in patients presenting with ischaemic stroke. This cohort is known to be at significant risk of venous thrombosis with rates up to 50%. 33 Furthermore, pulmonary emboli occur in 2% of these patients and are responsible for up to 25% of early deaths. [34] [35] [36] [37] Unfractionated and low molecular weight heparins reduce the incidence of VTE in stroke patients by up to 80% and significantly decrease rates of fatal and non-fatal PE. [38] [39] [40] [41] Small studies show differing results regarding bleeding risk and despite meta-analyses of these trials including a few thousand patients, they remain underpowered for determining if intracerebral bleeding is a significant risk when prophylactic heparin is administered. 42, 43 As a result of the indeterminate data, recommendations conflict. 44, 45 As a result of these conflicting and inconclusive data, physicians are understandably concerned that in reducing the risk of venous thrombosis in their patients, they may be increasing their risk of intracerebral bleeding into the original infarct and in turn, worsening their neurological outcome. At our Trust, despite the guidance of the RAM, stroke physicians rarely use prophylactic low molecular heparin within the first week following an ischaemic stroke due to the concerns of intracerebral bleeding.
During our series of audits, the percentage of patients presenting with stroke was markedly varied within each group. As this was an obvious confounding factor, the data were reassessed after excluding stroke patients from all groups. The number of strokes in each group was small and therefore the improvement in the rate of appropriate thromboprophylaxis was maintained.
Few of the stroke patients were wearing anti-embolism stockings, which might be an alternative method of thrombosis prevention in this high-risk group. Of 27 strokes in total, who did not receive low molecular weight heparin, only five had stockings in place. Of note, a recent study questioned the efficacy and safety of anti-embolism stockings after stroke; more research is required in this controversial area. 46 Age, another significant risk factor for VTE was also not heterogeneous across the audit groups. Although the age range was similar in all groups there was a greater percentage of patients over the age of 75 years in the first two audits, which is an important difference as the risk of VTE is known to be at its highest over this age. Physicians might be more reluctant to prescribe anti-coagulants in the elderly due to a perceived risk of bleeding. Alternatively, older people might be prescribed low molecular weight heparin more frequently prior to the RAM due to being regarded as at higher thrombotic risk than their younger counterparts, due to multiple risk factors, including their age. If this were the case, the greater number of elderly patients in the survey and Audit One compared with the two subsequent audits, would in fact improve the findings of the study.
The frequency of acute infectious and acute respiratory diseases was also not heterogeneous between the survey and audits. However, unlike for ischaemic stroke, there is unlikely to be any bias in thromboprophylaxis prescribing patterns for these two conditions except as a result of the RAM and its implementation.
Conclusions
Venous thrombosis is a common condition in hospitalized medical patients. Being hospitalized with an acute medical condition increased the risk of VTE 8-fold compared with the general population and one meta-analysis has demonstrated that the rate of VTE in medical in-patients may be as high as 20%. 1, 10 Furthermore, numerous studies concur that up to 80% of autopsy proven PE, contributing to a patient's death, occur in hospitalized patients who have not undergone recent surgery. [2] [3] [4] [5] There is now extensive evidence that low molecular weight heparin reduces this risk significantly, and therefore measures to improve the administration of this drug to the appropriate patients is of great importance. 24, 25 Few papers report the in-house use of a proforma to guide hospital clinicians in the use of thromboprophylaxis in medical patients but simply describe retrospective studies assessing adherence to national guidelines. [26] [27] [28] [29] 47 One study has reported the use of a risk assessment form to cover all emergency admissions, both medical and surgical, but showed little improvement in the completion of risk assessment for VTE. This was despite training junior medical staff in its use and subsequent assessment revealing them to be knowledgeable in the risks of VTE. 48 Our study is the first to audit the use of an exclusion-based RAM and demonstrate a consistent improvement in the administration of pharmacological thromboprophylaxis to the appropriate patients. This audit has also highlighted that, although there is strong evidence for the use of LMWH, there remain controversial areas for its use, namely ischaemic stroke. Further research is urgently required in this area.
Ideally, one RAM should be used for all hospitalized patients so that the procedure of VTE risk assessment is as straightforward as possible. This is recognized in the recent publication by the Chief Medical Officer of an evidence-based risk assessment template that can be applied to medical and surgical patients. 49 Our study preceded publication of this useful tool and reflects common practice in the UK, which recognizes that different patients groups might require different approaches to risk assessment. For example, the type of surgery performed on surgical patients has a significant impact on an individual's thrombotic risk and obstetric inpatients have many different risk factors for VTE that will not be found in other hospitalized patients, e.g. pre-eclampsia, hyperemesis, multiple pregnancies. 32, 50 The addition of more than one RAM to a hospital Trust does lead to complexity but this should be offset by each model providing the clearest risk assessment and most appropriate thromboprophylaxis for these patient groups.
The Department of Health last year issued a statement that all hospitalized patients must have a documented risk assessment for venous thrombosis performed on admission and prophylaxis prescribed where appropriate. 49 We have audited the uptake of appropriate thromboprophylaxis. It is now important that the completion of risk assessment is also audited to exclude the possibility that thromboprophylaxis is being prescribed on an ad hoc basis and also follow Department of Health guidelines. This would also provide the opportunity to document that risk assessment for VTE has been performed using a particular RAM. Furthermore, the administration of thromboprophylaxis must continued to be audited as the achievement of 100% risk assessment becomes meaningless unless thromboprophylaxis is shown to have been administered to all patients at high VTE risk.
Our study provides the first analysis of changes in rates of appropriate thromboprophylaxis following the introduction of an exclusion-based RAM for VTE in hospitalized medical patients. Although it cannot be directly proven that use of the RAM improved thromboprophylaxis rates, the absence of potential confounders makes it highly likely that the RAM, and the education of the junior doctors in its use led to the changes seen. It is therefore possible that such a model, if employed across the NHS, could lead to significant improvement in thromboprophylaxis uptake nationally and in turn, have a significant impact on the burden of VTE currently experienced in the UK.
